These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 10916387)
21. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2). Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623 [TBL] [Abstract][Full Text] [Related]
22. MIA, a novel serum marker for progression of malignant melanoma. Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221 [TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451 [TBL] [Abstract][Full Text] [Related]
24. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930 [TBL] [Abstract][Full Text] [Related]
26. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744 [TBL] [Abstract][Full Text] [Related]
27. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma. Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059 [TBL] [Abstract][Full Text] [Related]
28. Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large. Riechers A; Bosserhoff AK Exp Dermatol; 2014 Jan; 23(1):12-4. PubMed ID: 24372647 [TBL] [Abstract][Full Text] [Related]
29. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Missotten GS; Tang NE; Korse CM; Hurks HM; de Wolff-Rouendaal D; Keunen JE; Jager MJ; Bonfrer JM Arch Ophthalmol; 2003 Aug; 121(8):1117-9. PubMed ID: 12912688 [TBL] [Abstract][Full Text] [Related]
30. Circulating melanoma exosomes as diagnostic and prognosis biomarkers. Alegre E; Zubiri L; Perez-Gracia JL; González-Cao M; Soria L; Martín-Algarra S; González A Clin Chim Acta; 2016 Feb; 454():28-32. PubMed ID: 26724367 [TBL] [Abstract][Full Text] [Related]
32. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230 [TBL] [Abstract][Full Text] [Related]
33. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis. Szalai E; Wells JR; Ward L; Grossniklaus HE Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399 [TBL] [Abstract][Full Text] [Related]
34. VEGF as a biomarker for metastatic uveal melanoma in humans. Barak V; Pe'er J; Kalickman I; Frenkel S Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506 [TBL] [Abstract][Full Text] [Related]
35. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Cao MG; Auge JM; Molina R; Martí R; Carrera C; Castel T; Vilella R; Conill C; Sánchez M; Malvehy J; Puig S Anticancer Res; 2007; 27(1B):595-9. PubMed ID: 17348447 [TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans. Frenkel S; Zloto O; Pe'er J; Barak V Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):490-3. PubMed ID: 23197685 [TBL] [Abstract][Full Text] [Related]
37. [Serum markers for melanoma]. Ugurel S Hautarzt; 2005 Feb; 56(2):173-84; 185-6. PubMed ID: 15657726 [TBL] [Abstract][Full Text] [Related]
38. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389 [TBL] [Abstract][Full Text] [Related]
39. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664 [TBL] [Abstract][Full Text] [Related]
40. Nestin expression in primary and metastatic uveal melanoma - possible biomarker for high-risk uveal melanoma. Djirackor L; Shakir D; Kalirai H; Petrovski G; Coupland SE Acta Ophthalmol; 2018 Aug; 96(5):503-509. PubMed ID: 29338117 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]